Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 0.67 |
| ▸ | CA12 | O43570 | 2/20 | 0.67 |
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | CA3 | P07451 | 2/20 | 0.67 |
| ▸ | CA4 | P22748 | 2/20 | 0.67 |
| ▸ | CA6 | P23280 | 2/20 | 0.67 |
| ▸ | CA5A | P35218 | 2/20 | 0.67 |
| ▸ | CA7 | P43166 | 2/20 | 0.67 |
| ▸ | CA9 | Q16790 | 2/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.67 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2972851 | 1.00 | — | — | |
| SCHEMBL15177108 | 1.00 | DNM1 (0.67) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL29098464 | 1.00 | — | — | |
| SCHEMBL16152047 | 1.00 | DNM1 (0.67) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL2501714 | 1.00 | DNM1 (0.67) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL23697928 | 1.00 | DNM1 (0.67) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL1417018 | 1.00 | — | — | |
| SCHEMBL7639784 | 1.00 | DNM1 (0.67) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL31512201 | 1.00 | DNM1 (0.67) | DNM1CA12CA1CA2CA3 | |
| Hydrochloric Acid SCHEMBL22321635 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025091971-A1 | SOLAR CELL AND PREPARATION METHOD THEREFOR, PHOTOVOLTAIC MODULE, SYSTEM, AND APPARATUS | 宁德时代新能源科技股份有限公司 | 2025-05-08 | — | — | WO | claimed |
| CN-119923165-A | Solar cell, preparation method thereof, photovoltaic module, system and power utilization device | 宁德时代新能源科技股份有限公司 | 2025-05-02 | — | — | CN | claimed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | claimed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | claimed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | claimed |
| WO-2002006229-A2 | HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | claimed |
| WO-2025091971-A1 | SOLAR CELL AND PREPARATION METHOD THEREFOR, PHOTOVOLTAIC MODULE, SYSTEM, AND APPARATUS | 宁德时代新能源科技股份有限公司 | 2025-05-08 | — | — | WO | disclosed |
| CN-119923165-A | Solar cell, preparation method thereof, photovoltaic module, system and power utilization device | 宁德时代新能源科技股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-113045477-B | Preparation method of fluorine-containing primary amine intermediate | 中蓝晨光化工研究设计院有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-113045477-A | Preparation method of fluorine-containing primary amine intermediate | 中蓝晨光化工研究设计院有限公司 | 2021-06-29 | — | — | CN | disclosed |
| WO-2018094005-A1 | MYELOPEROXIDASE IMAGING AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20110245438-A1 | PRODUCTION PROCESS OF PRE-POLYMERIZED POLYMERIZATION CATALYST COMPONENT AND ADDITION POLYMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-10-06 | — | — | US | disclosed |
| US-6605618-B2 | Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction | WYETH | 2003-08-12 | — | — | US | disclosed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | disclosed |
| WO-2002006229-A2 | HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | DNM1 2973/4885CA12 4814/4885CA1 4874/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | DNM1 2385/4885CA12 4838/4885CA1 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.